Memo Therapeutics AG’s Post

Don't forget to register your attendance to the FREE Webinar with MarketOpen Australia that is being held tomorrow, Wednesday 24th July over Zoom. Dr Liz Dallimore will be providing an update on our Phase 2 clinical trial program. Learn more through the post below ⬇️ #AGN #ASX #stroke #clinicaltrial #strokeawareness #lifescience #investorupdate

New partnership announcement coming out of CincyTech portfolio company Enable Injections, Inc.! Enable Injections and Serina Therapeutics, Inc. are teaming up to revolutionize Parkinson's Disease treatment. 🧠💉 Their recent agreement aims to develop SER-252 in combination with enFuse, offering advanced solutions for those battling Parkinson's Disease. 🔍 SER-252, coupled with enFuse technology, promises groundbreaking advancements in Parkinson's treatment. With enhanced delivery methods, this collaboration could significantly improve patients' quality of life. Read more about this game-changing partnership here: https://lnkd.in/e4KYSJdZ #ParkinsonsDisease #MedicalInnovation #HealthcareAdvancements

🚨 New #DiabetesDialogue! 🚨 Hear from John Buse, MD, PhD, as he discusses why he says the 2-part CATALYST trial might be the "biggest thing that I have ever done in my career" with Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES and Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES. Get a deep dive into the trial, including part 2, which will examine use of mifepristone (Korlym; Corcept Therapeutics) among patients who screened positive for hypercortisolism. https://lnkd.in/et4uQuDg #Type2Diabetes #Hypercortisolism

The first pivotal trial of a CAR T cell therapy in first line will be given in community settings rather than exclusively in Centers of Excellence. It's an allogeneic product, meaning it's "off-the-shelf" ready. If this succeeds, it would address some critical limitations in CAR T cell therapy: individualized manufacturing bottlenecks (and costs due to non-scalability) and limited site availability associated with autologous cell therapies. Looking forward to the data disclosure in 2027! #Cancer #Oncology #CART #CellTherapies #Medicine https://lnkd.in/giFU2iZB +++ 👋 I’m Chris, a medical strategist, writer, and founder of Quill Science LLC. We use accurate and engaging storytelling to amplify the benefits of cutting-edge scientific and medical advances. 🌐 Check out www.quillscience.com and book a free discovery call. 💡 Follow me for science and medical news, perspectives, and career posts.

Block Clinical Inc. has been recommended by Friedreich's Ataxia Research Alliance (FARA) for our patient support and travel concierge services. Providing patients with rare diseases the best possible support and accommodations is necessary to conducting a successful clinical trial. Our patient support and travel services boost patient recruitment and retention by ensuring that every patient receives the necessary support and accommodations while enrolled in a clinical trial. Companies such as Design Therapeutics, PTC Therapeutics, Inc., and Prime Medicine, Inc. are spearheading research into Friedreich's Ataxia treatment. What types of patient support and travel services are being utilized in these trials? And how can we improve upon the standards of patient support within the rare disease market? #PatientSupport #ClinicalTrials #TravelConcierge #FriedreichAtaxia #PatientTravel #RareDisease

We’re looking forward to #ASCO24 next week! Biopharma leaders rely on The NemetzGroup LLC’s deep in-house commercialization and medical affairs experience to craft a holistic approach to knowing what to do, when, and why. In the ever-changing biopharma landscape, the flexible, custom support of The NemetzGroup keeps companies moving forward with confidence in their mission to serve patients. Connect with Raymond Mankoski, MD, PhD while you're in Chicago to learn more about how The NemetzGroup can help bring your cancer drug to life. #TheNemetzGroup #Biopharma #CommercializationPlanning

Many people have seen the Calm app on T.V., but what do you know about the apps that are actually FDA cleared and require a prescription? Here is a brief review of those apps cleared for use in mental health disorders. #digitalhealth #pharmacy #USCMann

Joint Clinical Assessment (JCA) is a central component of the new European Union health technology assessment (EU HTA) Regulation, which will streamline HTA across EU member states and play a major role in bringing new medical technology to market. In our whitepaper Lumanity experts explore the challenges of JCA, with particular focus on oncology, rare disease and advanced therapy medicinal products (ATMPs). https://buff.ly/45mgJE6 #LumanityPerspectives #HTA #JCA #HEOR #EUHTA

Struggling with the “Double-blinded placebo-controlled randomized controlled clinical trial for patients with Anal Intraepithelial Neoplasia (AIN),” Frantz Viral Therapeutics, a joint venture between Georgetown University Medical Center and Frantz Medical Group, faced numerous challenges while dealing with the trial phases. Moving ahead, they reached out to us with their concern over the ongoing challenges and sought help through Jeeva Clinical Trials Inc.'s eclinical solutions to accelerate their research. Learn how we accepted the challenges and, through our efficient and innovative solutions, assisted them in fulfilling their objectives from this case study: https://hubs.la/Q02gg2dj0 #RCT #clinicaltrials #AIN #healthtech #casestudy #randomizedclinicaltrial

It was terrific to kick off 2024 with a packed week at the J.P. Morgan Healthcare Conference. This event was a remarkable convergence of investors, candidates, and partners, each interaction paving the way for new ventures and collaborations. One of my highlights at the conference was participating in the WuXi AppTec panel entitled "Leading Transformation: Next Generation Therapeutics." It was an honor to share my views alongside leading experts on the industry and innovation, and to have the opportunity to speak about our pioneering science at Bitterroot Bio and the emerging field of cardio-immunology. Looking ahead, 2024 is set to be a transformational year for us as we mark a milestone with the entry of our lead program into first-in-human clinical trials. This step is more than just pipeline progress – it represents our hope that we can make a difference in the lives of millions of patients with cardiovascular disease. #JPM2024 #WuXiGlobalForum #BiotechInnovation #ClinicalTrials #HealthcareTransformation